VanEck Biotech ETF Newsroom

Disdained by the market! Goldman Sachs: Today's pharmaceutical stocks are like "Coal Industrial Concept during the ESG peak period".

Goldman Sachs traders believe that the current trading performance of pharmaceutical stocks resembles "Energy stocks at the peak of the ESG era - as if they are about to perish," with the Sector's valuation relative to the S&P 500 Index having fallen to a historic low, creating the largest discount on record.

wallstreetcn01:25 ET

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Benzinga15:58 ET

Shares of Pharmaceutical Stocks Are Trading Lower. The Sector May Down on Continued Weakness Amid President Trump's Drug Pricing Executive Order.

Benzinga15:27 ET

Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock

Benzinga15:00 ET

This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

BenzingaMay 14 08:58 ET

Regeneron Pharmaceuticals Analyst Ratings

BenzingaMay 14 08:20 ET · Ratings

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

BenzingaMay 13 12:15 ET

This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

BenzingaMay 13 08:47 ET

Astellas CEO on Outlook Ahead of Trump's Pharma Tariffs

BloombergMay 13 04:29 ET

"Don't sell if prices don't drop!" Trump enforces a mandatory minimum drug price for developed countries, but a lawsuit battle may be "reenacted".

① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.

cls.cnMay 12 20:52 ET

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

BenzingaMay 12 19:00 ET

The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.

① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.

cls.cnMay 12 12:33 ET

Roche Plans $700M North Carolina Facility

Seeking AlphaMay 12 10:53 ET

Innovation, Pharma Profits Won't Suffer Under Trump Prescription Drug EO - White House

Seeking AlphaMay 12 10:00 ET

Trump's Drug Price Cuts: Will They Work?

Moomoo News GlobalMay 12 09:35 ET

Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'

BenzingaMay 12 09:20 ET

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

BenzingaMay 12 07:20 ET

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

BenzingaMay 11 22:19 ET

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

BenzingaMay 11 09:46 ET

Notable Healthcare Headlines for the Week: Viatris, Novavax and UnitedHealth in Focus

Seeking AlphaMay 11 09:05 ET